Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Nov 25;8(11):e81594.
doi: 10.1371/journal.pone.0081594. eCollection 2013.

Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies

Yan-bo Chen  1 , Qi Chen, Zhong Wang, Juan Zhou
Affiliations
Meta-Analysis

Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies

Yan-bo Chen et al. PLoS One. .

Abstract

Background: Previous observational studies have shown that insulin therapy may modify the risk of prostate cancer (PCa). However, these studies yielded controversial results. Thus, we performed this meta-analysis to determine whether insulin use was associated with PCa risk in patients with diabetes mellitus (DM).

Method: A literature search was carried out in PubMed, EMBASE, and Cochrane Library Central database between January 1966 and January 2013. Fixed-effect and random-effect models were used to estimate pooled relative risks (RR) and corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analyses were also performed.

Result: A total of 11 (10 cohorts, and one case-control) studies published between 2007 and 2013 were included in the meta-analysis, representing data for 205,523 male subjects and 7,053 PCa cases. There were five studies investigating the influence of insulin and other glucose-lowering agents on the risk of PCa , and six studies investigating the influence of glargine and non-glargine insulin. Insulin use was not associated with PCa risk when compared with other glucose-lowering agents (RR=0.89, 95% CI, 0.72-1.09). Use of insulin glargine did not contribute to susceptibility to PCa as compared with use of non-glargine insulin (RR=1.26, 95% CI, 0.86-1.84). Sensitivity analysis confirmed the stability of present results, since no individual study affected the pooled result significantly.

Conclusions: Our results suggest that, there may be no significant association between insulin use and risk of PCa as compared with other glucose-lowering agents in patients with DM, and there was no substantial evidence for increase risk of PCa among insulin glargine users as compared to non-glargine insulin users. Further studies are warranted to validate these conclusions.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow diagram for study selection.
Figure 2
Figure 2. Forest plot: comparison of insulin vs. other glucose-lowering therapies and risk of prostate cancer.
Figure 3
Figure 3. Forest plot: comparison of insulin glargine vs. non-glargine insulins and risk of prostate cancer.
Figure 4
Figure 4. Funnel plots for publication bias.
A: Funnel plot for studies investigating insulin vs. other glucose-lowering agents and risk of prostate cancer. No publication bias was observed ( PBegg’s test= 0.327, PEgger’s test = 0.246) .B: Funnel plot for studies investigating insulin glargine vs. non-glargine and risk of prostate cancer. No publication bias was observed ( PBegg’s test= 0.851, PEgger’s test = 0.718). C: Filled funnel plot of comparison of insulin vs. other glucose-lowering therapies and risk of prostate cancer. The filled diamonds represent one presumed missing study.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855. - DOI - PubMed
    1. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388-1413. doi:10.2741/1891. PubMed: 16368524. - DOI - PubMed
    1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40. doi:10.1016/S0140-6736(11)60679-X. PubMed: 21705069. - DOI - PubMed
    1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321. doi:10.1016/j.diabres.2011.10.029. PubMed: 22079683. - DOI - PubMed
    1. Tseng CH (2011) Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men. Ann Med 43: 142-150. doi:10.3109/07853890.2010.530683. PubMed: 21284526. - DOI - PubMed